American Society of Clinical Oncology (ASCO)

The American Society of Clinical Oncology (ASCO) is a professional organization representing physicians of all oncology sub-specialties who care for people with cancer. Founded in 1964 by Fred Ansfield, Harry Bisel, Herman Freckman, Arnoldus Goudsmit, Robert Talley, William Wilson, and Jane C. Wright, it has nearly 45,000 members worldwide.

Racial Disparities in Follow-Up Care of Early-Stage Lung Cancer Survivors

ASCO 2021 – Lung Cancer

Significant racial disparities exist among lung cancer survivors in receipt of surveillance scans, guidance about follow-up care, and smoking cessation. Read More ›

ASCO 2021 – Lung Cancer

Findings from KEYNOTE-598 detected no difference in health-related quality of life or time to true deterioration in lung cancer symptoms comparing treatment with pembrolizumab + ipilimumab versus pembrolizumab + placebo in patients with previously untreated metastatic non–small-cell lung cancer (NSCLC) with PD-L1 tumor proportion score ≥50%. Read More ›

Clinical Utility of Cell-Free Genomic Profiling in Advanced Lung Adenocarcinoma

ASCO 2021 – Lung Cancer

Findings of the prospective community-based observational NILE study support the use of cfDNA to identify actionable genomic alterations in newly diagnosed patients with advanced lung adenocarcinoma. Read More ›

CodeBreaK 100: Efficacy Results from a Phase 2 Trial in Pretreated KRAS G12C–Mutated NSCLC

ASCO 2021 – Lung Cancer

Sotorasib, an oral KRAS inhibitor, was effective across specified subgroups of patients with KRAS G12C–mutated non–small-cell lung cancer (NSCLC). Read More ›

Cost Evaluation of Adjunctive Osimertinib Use in Resected EGFR-Positive NSCLC

ASCO 2021 – Lung Cancer

The cost burden of adjunctive osimertinib therapy is higher than the observed clinical benefit for patients with resected EGFR-positive non–small-cell lung cancer (NSCLC). Read More ›

Active Multimodal Intervention Reduced Racial Disparities in Delivery of Timely Lung Cancer Surgery

ASCO 2021 – Lung Cancer

The ACCURE intervention using a combination of real-time electronic health record monitoring, nurse navigation, and race-based feedback significantly improved delivery of timely lung cancer surgery and markedly reduced racial disparities for patients with early-stage lung cancer. Read More ›

EGFR and MET Combined Inhibition in EGFR-Mutated Advanced NSCLC: A Real-World Study

ASCO 2021 – Lung Cancer

The combination of EGFR-tyrosine kinase inhibitor (TKI) and MET-TKI therapy improves clinical outcomes in patients who developed MET amplification after prior EGFR-TKI therapy in EGFR-mutated non–small-cell lung cancer (NSCLC). Read More ›

CheckMate-9LA: Nivolumab + Ipilimumab in Advanced NSCLC – Two-Year Update

ASCO 2021 – Lung Cancer

First-line use of nivolumab + ipilimumab in patients with advanced non–small-cell lung cancer (NSCLC) offers durable survival relative to chemotherapy alone with ≥2 years of follow-up. Read More ›

Racial Disparities in Lung Adenocarcinoma: The Contribution of African Ancestry

ASCO 2021 – Lung Cancer

Findings of a global ancestry analysis confirm that African ancestry is associated with worse survival outcomes among patients with lung adenocarcinoma. Read More ›

Clinical Trial Enrollment and Biomarker Testing in NSCLC: Racial Disparities

ASCO 2021 – Lung Cancer

Comprehensive biomarker testing and clinical trial participation rates were significantly lower for black patients in the United States compared with white patients with advanced non–small-cell lung cancer (NSCLC). Read More ›

American Society of Clinical Oncology (ASCO)

Page 6 of 29